Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction

Survodutide, an investigational dual agonist, targets both the glucagon receptor and GLP-1 receptor.

• Survodutide shows promise in managing obesity and metabolic dysfunction-associated steatohepatitis (MASH).
• The dual activation of glucagon and GLP-1 receptors may enhance metabolic benefits compared to selective GLP-1 receptor agonists.
• Clinical trials indicate that survodutide is generally well tolerated, with primarily manageable gastrointestinal side effects.
• Efficacy in promoting fibrosis regression in MASH remains to be proven as survodutide advances through phase 3 clinical development.

AI simplified